Jade Biosciences, Inc. Common Stock JBIO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $109.15M+17.2% | $93.12M-2.8% | $95.81M+9.6% | $87.39M+34.6% | $64.92M-0.1% | ||
| $24.45M+19.7% | $20.42M+11.7% | $18.29M+28.1% | $14.28M+49.4% | $9.56M-11.0% | ||
| $133.6M+17.7% | $113.54M-0.5% | $114.1M+12.2% | $101.67M+36.5% | $74.48M-1.6% | ||
| -$133.6M-17.7% | -$113.54M+0.5% | -$114.1M-12.2% | -$101.67M-36.5% | -$74.48M+1.6% | ||
| —— | —— | -$28.36M+11.1% | -$31.89M-15.8% | -$27.54M-143% | ||
| —— | —— | —— | —— | —— | ||
| $59.5K+2.6% | $58K+33.3% | $43.5K— | —— | —— | ||
| -$129.61M-1.7% | -$127.41M+10.6% | -$142.46M-6.7% | -$133.56M-30.9% | -$102.02M-17.2% | ||
| -$2.02+85.1% | -$13.55+52.2% | -$28.33+14.2% | -$33.01-2.1% | -$32.34-53.5% | ||
| -$133.57M-17.7% | -$113.52M+0.5% | -$114.08M-12.5% | -$101.43M-36.7% | -$74.22M+1.6% | ||
| -$133.6M-17.7% | -$113.54M+0.5% | -$114.1M-12.2% | -$101.67M-36.5% | -$74.48M+1.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Jade Biosciences, Inc. Common Stock profitable?
- Jade Biosciences, Inc. Common Stock is not currently profitable: it reported a net loss of $129.6M over the trailing twelve months.
- What is Jade Biosciences, Inc. Common Stock's earnings per share?
- Jade Biosciences, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.02.
- Where does Jade Biosciences, Inc. Common Stock's income statement data come from?
- Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.